Better care today, transformative treatments tomorrow
Axovant is rapidly developing innovative gene therapy products that address devastating neurological diseases with significant unmet medical needs. We are currently studying gene therapy candidates for Tay-Sachs disease, Sandhoff disease and Parkinson’s Disease in clinical trials and are working quickly to bring our gene therapy candidates for GM1 gangliosidosis to patients in the clinic. For more information about our ongoing clinical trials for these investigational therapies, please visit www.clinicaltrials.gov and search for “Axovant.” If you have questions about participating in our clinical trials, please speak with your physician.
Expanded access refers to the use of an investigational therapy - one which has not yet obtained regulatory approval - for an individual patient outside of a clinical trial setting, whereas the use of investigational therapy in a clinical trial setting involves the collection and assessment of comprehensive safety and efficacy data in clinical trial subjects over a period of time in well controlled matter, generally to support an application for regulatory approval.
At this time, Axovant believes that participation in one of its clinical trials is the most appropriate way to access it investigational therapies. Therefore, Axovant does not have an expanded access program. If you have questions about participating in our clinical trials, please speak with your physician or visit www.clinicaltrials.gov.
Consistent with the 21st Century Cures Act, Axovant reserves the right to revise this policy at any time.
In addition, you can also contact us directly at firstname.lastname@example.org.